NeuroMetrix, a pioneer in neurotechnology, is pleased to announce the publication of results from a Phase 2 clinical trial of Quell in the prestigious Journal of Pain. This groundbreaking study, funded by the National Institutes of Health (NIH), demonstrates that Quell effectively improves the painful symptoms associated with Chemotherapy Induced Peripheral Neuropathy (CIPN). The findings of this peer-reviewed publication bring hope to millions of cancer patients undergoing chemotherapy.
Chemotherapy is a cornerstone of modern cancer treatment, but its debilitating side effects often outweigh its benefits. CIPN, a common adverse effect of chemotherapy, affects approximately 30-40% of patients, causing severe pain and sensory disturbances in the limbs. Until now, there has been no definitive solution to address this excruciating condition.
The clinical trial, led by top scientists, aimed to evaluate the effectiveness of Quell, NeuroMetrix’s groundbreaking wearable device designed to alleviate chronic pain. The trial involved 150 patients who were randomly assigned to receive either active Quell therapy or a placebo. The results were nothing short of extraordinary. Patients using Quell reported significantly reduced pain levels and improved overall quality of life compared to those using the placebo.
Quell works by utilizing innovative neurostimulation technology to target the nerves responsible for CIPN-related pain. The device is worn on the leg and utilizes patented OptiTherapy technology to deliver precise and optimal pain relief. Quell users have the option to control the therapy using a smartphone app, enabling them to personalize their treatment to suit their specific needs.
The publication of these findings in The Journal of Pain further solidifies the scientific community’s confidence in Quell as a viable treatment option for CIPN. NeuroMetrix’s CEO, Dr. Shai N. Gozani, expressed his enthusiasm, stating, We are thrilled to share the results of this study, as it validates Quell’s ability to address the severe pain associated with CIPN. This represents a significant step forward in improving the lives of cancer patients undergoing chemotherapy.
The impact of this breakthrough cannot be overstated. Quell’s ability to provide relief for chemotherapy-induced peripheral neuropathy will greatly alleviate the suffering experienced by cancer patients and improve their quality of life. This treatment option offers hope and a new lease on life to those battling this devastating condition.
Looking ahead, NeuroMetrix plans to continue its research efforts to refine Quell and explore its efficacy on other types of chronic pain. The company aims to revolutionize pain management and provide innovative solutions that enhance the well-being of individuals worldwide.
Comments